CYC First-Half 2026 Update
Filed with ASX · · 6 pages · English
Summary by 6ix AI
Cyclopharm Limited has released an update on its first-half revenue performance for the fiscal year, reporting record revenues and significant growth in its US Technegas® installations. The company noted that while revenues increased, guidance for US installations has been deferred due to delays in the approval of clinical guidelines.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Story so far
Earlier from Cyclopharm
- USA Technegas Expansion Update
- CYC Secures Multi-Site Agreement with Northwestern Medicine
- CYC Signs Enterprise Agreement with UPHS
- Preliminary Final Report
- Technegas US Footprint Expanding Across Four Regions
Later from Cyclopharm
- Immediate 11-Site Technegas Rollout at University Hospitals
- New US Lung Imaging Guidelines Name Technegas as Preferred A
- CYC 1H2026 Results Summary
- Chinese Consensus Names Technegas Preferred Lung Agent
- Cyclopharm Q3 2026 Update
Follow Cyclopharm into a list and get an email when it puts out news.
Follow Cyclopharm